Findings

What do systematic reviews say?

247 questions · 258 findings · 21 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 84 · 32.6%GRADE not reported 12 · 4.7%Very low 78 · 30.2%Low 56 · 21.7%Moderate 22 · 8.5%High 6 · 2.3%

Intravenous magnesium sulphate vs placebo

HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 202 participants
Low

Intravenous magnesium sulphate vs placebo

Length of hospital stay · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Low

Intravenous magnesium sulphate vs placebo

Hypotension · people with sickle cell disease

Intravenous magnesium sulphate showed no clear difference in adverse effects: hypotension compared with placebo (low certainty).

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
RR 2.57 [0.5, 13.08]
2 studies · 306 participants
Low

Intravenous magnesium sulphate vs placebo

Adverse effects: warmth at infusion site · people with sickle cell disease

Intravenous magnesium sulphate may leads to higher adverse effects: warmth at infusion site compared with placebo (low certainty).

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
RR 13.26 [3.23, 54.4]
1 study · 202 participants
Low

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

Time to recovery · children up to 12 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

All‐cause mortality · children up to 12 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

Adverse events · children up to 12 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

Length of hospital stay · children up to 12 months old with acute bronchiolitis

It is very uncertain whether magnesium sulphate + epinephrine changes duration of hospital stay compared with no treatment or normal saline + epinephrine (very low certainty).

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Very low

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured at 0 to 24 hoursafter treatment · children up to 12 months old with acute bronchiolitis

It is very uncertain whether magnesium sulphate + epinephrine changes clinical severity score (CSS) (RDAI score; range 0 to 17; higher =… compared with no treatment or normal saline + epinephrine (very low certainty).

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Very low

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured 25 to 48 hoursafter treatment · children up to 12 months old with acute bronchiolitis

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Very low

Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine

Hospital re‐admission within 30 days of discharge · children up to 12 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium citrate vs placebo

Risk of acute mountain sickness · participants at risk of high altitude illness

Magnesium citrate showed no clear difference in risk of acute mountain sickness compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
RR 1.09 [0.55, 2.13]
1 study · 70 participants
Low

Magnesium citrate vs placebo

Risk of high altitude pulmonary oedema · participants at risk of high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium citrate vs placebo

Risk of high altitude cerebral oedema · participants at risk of high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium citrate vs placebo

Risk of adverse events: Loose stools · participants at risk of high altitude illness

Magnesium citrate may leads to higher risk of adverse events: Loose stools compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
RR 3.25 [1.17, 8.99]
1 study · 70 participants
Low

Magnesium aspartate vs placebo

Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use

It is very uncertain whether magnesium aspartate changes benzodiazepine discontinuation, end of intervention compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
RR 0.8 [0.66, 0.96]
1 study · 144 participants
Very low

Magnesium aspartate vs placebo

Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Magnesium aspartate vs placebo

Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Magnesium aspartate vs placebo

Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use

1 finding from 1 review

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Nebulised magnesium sulfate + standard care vs placebo + standard care

Proportion of people requiring ventilatory support (NIV or assisted ventilation) · acute exacerbations of chronic obstructive pulmonary disease

It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ventilatory support (NIV or assisted… compared with placebo + standard care (very low certainty).

1 finding from 1 review

Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease 2022 · Cochrane Headline outcomes only
OR 0.33 [0.01, 8.2]
1 study · 172 participants
Very low